ASCO 2026: Unprecedented Seven-Year Results from CROWN Redefine ALK-Positive NSCLC Treatment

The treatment paradigm for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) has evolved dramatically with the advent of next-generation tyrosine kinase inhibitors (TKIs). The phase III CROWN study established lorlatinib as a highly effective first-line therapy, delivering durable systemic and intracranial disease control. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, updated seven-year follow-up results revealed a median progression-free survival (mPFS) not yet reached and a seven-year progression-free survival (PFS) rate of 55%. Importantly, the study also demonstrated a seven-year intracranial progression-free survival (PFS) rate of 92%, highlighting sustained central nervous system (CNS) protection. The concept of the “ALK diamond mutation” reflects the favourable prognosis associated with ALK-rearranged NSCLC, symbolising the profound therapeutic benefit afforded by modern targeted agents. This article reviews the long-term CROWN data and discusses their implications for clinical practice.

Introduction

ALK-positive NSCLC accounts for approximately 3–5% of lung cancers and is characterised by oncogenic rearrangements of the ALK gene.1 Historically, advanced NSCLC carried a poor prognosis; however, targeted therapies have revolutionised outcomes in this molecular subset.2

Today, the identification of an ALK rearrangement is often considered a “diamond” in lung cancer diagnosis. Despite the seriousness of metastatic disease, patients with ALK-positive tumours benefit from highly effective, relatively low-toxicity therapies that can produce deep responses and long-term survival. This favourable biology, combined with therapeutic advances, has reshaped expectations for disease control.3

Overview of the CROWN Study

The global phase III CROWN trial compared lorlatinib, a third-generation ALK TKI, with crizotinib in treatment-naïve patients with advanced ALK-positive NSCLC. Initial and subsequent analyses consistently demonstrated superior efficacy with lorlatinib, including improved progression-free survival and intracranial response rates.3

Lorlatinib was rationally designed to overcome limitations of earlier ALK inhibitors, particularly resistance mutations and inadequate CNS penetration.

Lorlatinib has a compact, macrocyclic structure to physically overcome the steric hindrance and conformational binding shifts caused by mutations (like G1202R) that defeat earlier inhibitors.4 When used in the first-line settings, because the cancer has not been previously exposed to or "sculpted" by earlier, weaker targeted therapies, it rarely harbours the complex or compound on-target mutations (like the deadly G1202R solvent-front mutation).5 Lorlatinib is highly potent and effectively shuts down the primary ALK driver so completely that the cancer's primary escape route is no longer through altering the ALK target site itself.6 Instead of secondary ALK mutations, resistance—when it eventually occurs—is often driven by off-target or "bypass" signalling pathways that allow the tumour to grow independently of ALK.7

Lorlatinib is also highly lipophilic, specifically engineered to cross the blood-brain barrier, achieving high concentrations in the brain. Unlike older-generation drugs that accidentally or poorly crossed into the brain, lorlatinib was meticulously optimised from the ground up for CNS penetration using structure-based drug design and physicochemical parameter tuning.4

Seven-Year Efficacy Outcomes

Progression-Free Survival

The seven-year follow-up presented at ASCO 2026 provides unprecedented insight into long-term outcomes. The median progression-free survival remains unreached after seven years, indicating sustained benefit in a majority of patients. This represents a landmark achievement in metastatic NSCLC. The seven-year PFS rate of 55% further underscores the durability of response, suggesting that more than half of patients treated with first-line lorlatinib remain progression-free at this extended time point (Figure 1). Surprisingly, if the patients are progression-free by the second year, they will have approximately a 79% chance that they may remain progression-free at the end of the seventh year.6,8

These findings support the concept that ALK-positive NSCLC can be managed as a chronic condition in many patients. Early initiation of a highly potent TKI such as lorlatinib appears critical to achieving maximal long-term benefit.8

Central Nervous System Protection

CNS involvement is common in ALK-positive NSCLC and remains a major clinical challenge. Lorlatinib’s ability to penetrate the blood-brain barrier has translated into exceptional intracranial disease control. The CROWN study reported a seven-year intracranial progression-free survival rate of 92%, reflecting durable and sustained protection against CNS progression.8

This high level of intracranial control reduces the need for local CNS therapies, such as radiation or surgery, which are associated with potential neurocognitive side effects. As a result, patients can maintain better neurological function and overall quality of life over time.8

The Concept of the ALK “Diamond Mutation”

A Symbol of Therapeutic Opportunity

The term “ALK diamond mutation” is used metaphorically to describe the uniquely favourable clinical outlook associated with ALK rearrangements. While advanced NSCLC is typically a severe diagnosis, the presence of an ALK alteration represents a “diamond” because:9,10

• Targeted therapies yield exceptionally high response rates

• Patients often experience prolonged survival

• Treatments are generally well tolerated compared with traditional chemotherapy

Transforming Prognosis

The availability of potent TKIs like lorlatinib and alectinib has fundamentally altered the natural history of this disease. Patients with ALK-positive NSCLC now frequently achieve long-term disease control, redefining expectations for metastatic cancer.8,10

Importance of Early Detection

This concept highlights the critical role of comprehensive molecular testing.11 Identifying ALK rearrangements at diagnosis enables timely initiation of optimal therapy, significantly improving outcomes.12

Comparative Context

Compared with earlier generations of ALK inhibitors, third-generation agents demonstrate clear advantages:

• Crizotinib (first-generation): Limited durability and poor CNS penetration13

• Second-generation inhibitors: Improved outcomes but eventual resistance14

• Third-generation inhibitors: Superior long-term PFS and exceptional intracranial efficacy. The seven-year data from CROWN firmly establish lorlatinib as a leading first-line standard of care6,8

Figure 1: PFS by investigator assessment in intention-to-treat population6. CI: confidence interval; HR: hazard ratio; NR: not reached; PFS: progression free survival

Safety and Tolerability

The safety profile of lorlatinib was similar to that reported in the primary analysis of CROWN and in subsequent follow-up analyses, with no new safety signals detected-suggesting no cumulative toxicity-with additional follow-up.6,15 Lorlatinib has a manageable safety profile, though it requires careful monitoring. Common adverse events include hyperlipidaemia, cognitive and mood effects, and peripheral oedema. These side effects are generally manageable with dose adjustments and supportive care, allowing most patients to continue long-term therapy.6

Implications for Clinical Practice

The updated findings from the CROWN study have several key implications:

• Frontline ALK Inhibitors: Early use maximizes both systemic and intracranial control

• CNS-First Strategy: Preventing intracranial progression is essential in optimising long-term outcomes

• Routine Molecular Testing: Detecting ALK alterations is critical to unlocking effective targeted therapy

• Chronic Disease Management: Long-term therapy requires ongoing monitoring and multidisciplinary care

Conclusion

The seven-year follow-up of the CROWN study represents a milestone in the treatment of ALK-positive NSCLC. With a median PFS not yet reached and a seven-year PFS rate of 55%, lorlatinib provides unprecedented durability of disease control. Its remarkable 92% seven-year intracranial progression-free survival rate highlights its ability to protect against CNS progression, a key determinant of patient outcomes.

The concept of the ALK “diamond mutation” encapsulates the optimism now associated with this disease subtype. Although metastatic NSCLC remains serious, patients with ALK rearrangements benefit from highly effective targeted therapies that enable prolonged survival and preserved quality of life.

These findings reinforce lorlatinib’s role as a transformative therapy and set a new benchmark for long-term outcomes in precision oncology.

References: 1. Cognigni V, et al. Cancers (Basel). 2022;14(19):4765. 2. Long M, et al. Cancer Drug Resist. 2025;8:43. 3. Wu YL, et al. J Thorac Oncol. 2025;20:955–68. 4. Akamine T, et al. Onco Targets Ther. 2018;11:5093–101. 5. Kobayashi K. J Respir. 2026; 6(2): 11. 6. Shaw AT, et al. Ann Oncol. 2026 May 29:S0923-7534(26)00876-8. doi: 10.1016/j.annonc.2026.05.692. Online ahead of print. 7. Wu L, et al. Transl Lung Cancer Res. 2026;15(1):5. 8. Mok TSK, et al. J Clin Oncol. 2026;44(Suppl.16):8502. 9. Liao S, et al. Front Oncol. 2022;12:916315. 10. Peters S, et al. Ann Oncol. 2026;37(1):92–103. 11. Parvaresh H, et al. Biomedicines. 2024;12(2):297. 12. Griesinger F, et al. Oncotarget. 2018:9(80);35181–94. 13. Yoshida T, et al. Lung Cancer. 2016; 97:43–7. 14. Pan Y, et al. Front Oncol. 2021;11:713530. 15. Shaw AT, et al. N Engl J Med. 2020;383(21):2018–29.